Anxiolytics: Pharmacology, Rational Use and Dependence-Safe Prescribing
On this page
1 Overview
Anxiolytics reduce pathological anxiety. The pharmacological story is one of progressive refinement: barbiturates (dangerous, narrow index) gave way to benzodiazepines (effective and far safer in overdose, but habit-forming), which are now complemented — and for chronic anxiety largely replaced — by SSRIs and buspirone (slow but non-dependence-forming). Safe prescribing therefore means two disciplines: knowing the drugs, and knowing how to keep benzodiazepine use short, purposeful and reviewed.


2 Learning Objectives
- Explain how benzodiazepines, buspirone and other anxiolytics act, and what distinguishes dependence-forming from non-dependence-forming agents.
- Classify benzodiazepines by duration and match agents to indications.
- Prescribe benzodiazepines safely: indications, duration limits, tapering and review.
- Manage benzodiazepine overdose and describe the limited, risky role of flumazenil.
- Choose rationally for special groups — elderly, pregnancy, substance-use history.
3 GABA Pharmacology — the Target of Anxiolysis
GABA is the brain's principal inhibitory neurotransmitter. GABAA receptors are ligand-gated chloride channels; when GABA binds, chloride influx hyperpolarises the neuron. The GABAA complex carries binding sites for several drug classes: benzodiazepines (bind between α and γ subunits), barbiturates (bind elsewhere on the receptor), neurosteroids, alcohol and the Z-drugs. GABAB receptors are metabotropic (G-protein-coupled) — baclofen is their clinical ligand; benzodiazepines do not act there. Two mechanism facts explain most clinical behaviour: benzodiazepines increase the frequency of chloride-channel opening in response to GABA (they are positive allosteric modulators — they need GABA present, which is why they are safe in overdose alone), while barbiturates prolong opening and can directly gate the channel at high dose — which is why barbiturate overdose is lethal and benzodiazepine overdose usually is not.
4 Benzodiazepines
Classification by duration
Scroll the table sideways on a smaller screen.
| Duration | Agents | Typical use |
|---|---|---|
| Short-acting | Midazolam, triazolam | Procedural sedation; brief insomnia |
| Intermediate | Lorazepam, alprazolam, temazepam, oxazepam | Lorazepam: status, alcohol withdrawal; alprazolam: panic (high potency, difficult withdrawal); temazepam/oxazepam: insomnia, elderly-friendly (glucuronidation) |
| Long-acting | Diazepam, chlordiazepoxide, clonazepam | Anxiety, alcohol withdrawal (diazepam, chlordiazepoxide), epilepsy (clonazepam) |
Indications
Acute situational anxiety and panic, generalised anxiety (short-term), insomnia (short-term), status epilepticus and seizure clusters, alcohol withdrawal, muscle spasm, procedural sedation, agitation (cautiously). They are not the treatment for chronic anxiety disorders, PTSD or depression — SSRIs are.
Adverse effects and hazards
- CNS — sedation, psychomotor impairment, anterograde amnesia, paradoxical disinhibition (children, elderly), falls and hip fractures in the elderly, driving impairment.
- Respiratory — dose-dependent depression; dangerous with alcohol, opioids and other sedatives (additive GABA effects).
- Dependence — tolerance within days to weeks (receptor downregulation), psychological and physical dependence; withdrawal on stopping after regular use beyond a few weeks: rebound anxiety, insomnia, tremor, perceptual disturbance, and seizures and delirium in severe withdrawal — potentially life-threatening.
- Special notes — alprazolam's short half-life and high potency make dependence and interdose withdrawal particularly severe; diazepam's active metabolites extend its effect for days in elderly patients.
Dependence and withdrawal
Withdrawal risk rises with dose, potency, duration (>4–6 weeks) and abrupt cessation. Management is a taper — typically reducing by ~10–25% of the dose every 1–2 weeks (switching to the long-acting diazepam first smooths the process), often over weeks to months with psychological support. Buspirone and pregabalin can help some patients during discontinuation; buspirone does not treat established benzodiazepine withdrawal (no GABA action).
5 Flumazenil — the Antidote with Strings Attached
Flumazenil is a competitive benzodiazepine-receptor antagonist: onset 1–2 minutes, peak 6–10 minutes, duration 20–50 minutes. It reverses sedation from conscious sedation and can diagnose/awaken in pure, known, single-agent benzodiazepine overdose. Its risks are decisive: seizures in chronic benzodiazepine-dependent patients (precipitates withdrawal — and then benzodiazepines won't work, since receptors are blocked); seizures with TCA or pro-convulsant co-ingestion; panic attacks in panic-disorder patients; re-sedation as it wears off before long-acting benzodiazepines clear. Contraindicated in mixed/unknown overdose, TCA co-ingestion, chronic dependence, seizure disorder, head injury. In practice, most benzodiazepine overdoses are managed with supportive care and airway protection, and flumazenil use is diminishing because the harms can outweigh the benefits.
6 Non-Benzodiazepine Options for Anxiety
- SSRIs/SNRIs — first-line for chronic anxiety disorders (GAD, panic, social anxiety, PTSD): effective, non-dependence-forming, treat comorbid depression. Cost: 2–4 weeks to onset, initial jitteriness, sexual dysfunction.
- Buspirone — a 5-HT1A partial agonist with no GABA activity: anxiolytic for GAD without sedation, amnesia, respiratory depression, or dependence/withdrawal; onset 2–4 weeks (not useful acutely); dizziness, nausea, headache; may augment SSRIs and blunt their sexual side effects; no value in benzodiazepine, alcohol or barbiturate withdrawal; avoid with MAOIs.
- Hydroxyzine — sedating antihistamine; useful short-term, anticholinergic burden limits elderly use.
- Propranolol — blocks peripheral adrenergic symptoms (tremor, tachycardia, sweating) for performance anxiety; not generalised treatment; caution in asthma and diabetes.
- Pregabalin — effective for GAD (α2δ calcium-channel binding); sedation and misuse potential at higher doses; also treats neuropathic pain.
- Z-drugs (zolpidem, zopiclone) — α1-selective GABAA agonists for insomnia, not anxiety; lower dependence than benzodiazepines but not dependence-free (complex sleep behaviours with zolpidem).
- Psychological therapy — CBT is first-line alongside SSRIs for anxiety disorders, and is the treatment of choice for benzodiazepine discontinuation support.
7 Drug Monographs: Doses, Indications & Safety
Full monograph for each key anxiolytic, in the standard structure: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.
Diazepam (long-acting benzodiazepine)
Scroll the table sideways on a smaller screen.
| Diazepam — GABAA positive allosteric modulator | |
|---|---|
| Mechanism | Potentiates GABA at GABAA receptors → increased chloride-channel opening frequency; long-acting with active metabolites (desmethyldiazepam) |
| Indications | Short-term anxiety, alcohol withdrawal, muscle spasm, status epilepticus (IV/rectal), pre-procedure sedation |
| Adult dose | Anxiety: 2–5 mg 2–3 times daily; status: 10–20 mg slow IV or rectal; alcohol withdrawal: 10–20 mg 2–4 times daily, then taper over 5–7 days; pre-procedure: 5–15 mg oral |
| Paediatric dose | Status febrile convulsions: 0.2–0.5 mg/kg rectal (max 10 mg); not for chronic anxiety in children |
| Adverse effects | Sedation, drowsiness, ataxia, amnesia, dependence with regular use; accumulates in the elderly (active metabolites) |
| Contraindications | Severe respiratory insufficiency, sleep apnoea, myasthenia gravis; caution in elderly, hepatic impairment, pregnancy |
| Interactions | Additive with alcohol, opioids, other CNS depressants; CYP2C19/3A4 inhibitors (fluconazole, some antiretrovirals) raise levels; enzyme inducers (rifampicin, carbamazepine, phenytoin) lower its levels |
| Patient advice / monitoring | Shortest possible course; never mix with alcohol; no driving until stable; do not stop abruptly after regular use — taper; extra caution in the elderly (falls, confusion) |
Lorazepam (intermediate benzodiazepine)
Scroll the table sideways on a smaller screen.
| Lorazepam — GABAA positive allosteric modulator | |
|---|---|
| Mechanism | Same GABAA mechanism; glucuronidated — no active metabolites, more predictable in liver disease and the elderly |
| Indications | Status epilepticus (first-line), panic and acute anxiety, alcohol withdrawal, agitation, pre-procedure |
| Adult dose | Status: 4 mg IV (0.1 mg/kg), repeat once after 10 min; anxiety: 0.5–2 mg 2–3 times daily; withdrawal: 1–2 mg 4 times daily tapering; sedation: 2–4 mg IM |
| Paediatric dose | Status: 0.1 mg/kg IV (max 4 mg); anxiety: 0.05 mg/kg/day divided (specialist, short-term) |
| Adverse effects | Sedation, amnesia, paradoxical agitation (children/elderly), dependence, respiratory depression with other sedatives |
| Contraindications | As diazepam (respiratory failure, sleep apnoea, myasthenia gravis) |
| Interactions | Additive CNS/respiratory depression with opioids, alcohol, antihistamines, antipsychotics; valproate and probenecid raise levels |
| Patient advice / monitoring | Preferred benzodiazepine in liver disease and the elderly; short courses only; taper on stopping; avoid driving/sedating co-drugs |
Alprazolam (high-potency intermediate benzodiazepine)
Scroll the table sideways on a smaller screen.
| Alprazolam — GABAA positive allosteric modulator | |
|---|---|
| Mechanism | High-affinity GABAA potentiation; high potency with short half-life and rapid onset → strong reinforcement |
| Indications | Panic disorder (with/without agoraphobia); not recommended for generalised long-term anxiety |
| Adult dose | 0.25–0.5 mg 3 times daily; usual max 3–4 mg/day; lowest dose, shortest course |
| Paediatric dose | Not recommended |
| Adverse effects | Sedation, dependence and severe interdose withdrawal (rebound anxiety between doses), amnesia, depression |
| Contraindications | As other benzodiazepines; avoid with substance-use history |
| Interactions | Same additive-sedation profile; CYP3A4 inhibitors (ketoconazole, ritonavir) raise levels; CYP3A4 inducers (carbamazepine, rifampicin) lower them |
| Patient advice / monitoring | The most dependence-forming benzodiazepine in common use — prescribe few tablets, fixed short duration, review; never stop abruptly (seizure risk) |
Clonazepam (long-acting benzodiazepine)
Scroll the table sideways on a smaller screen.
| Clonazepam — GABAA positive allosteric modulator | |
|---|---|
| Mechanism | Same GABAA mechanism; long half-life (~30–40 h) gives smooth, sustained effect |
| Indications | Myoclonic and absence epilepsy, adjunct in focal epilepsy, anxiety (short-term), restless legs |
| Adult dose | Start 0.5 mg 3 times daily or 1 mg at night; usual 1–8 mg/day in 1–3 divided doses |
| Paediatric dose | Start 0.01–0.03 mg/kg/day (max 0.05 mg/kg/day) in 2–3 divided doses |
| Adverse effects | Sedation, ataxia, behavioural change, dependence with long-term use; tolerance develops |
| Contraindications | As other benzodiazepines |
| Interactions | Additive sedation; inducers (carbamazepine, phenytoin, rifampicin) lower its levels |
| Patient advice / monitoring | Take consistently; do not stop abruptly (rebound seizures); review necessity regularly — tolerance limits long-term benefit |
Midazolam (short-acting benzodiazepine)
Scroll the table sideways on a smaller screen.
| Midazolam — GABAA positive allosteric modulator | |
|---|---|
| Mechanism | Same GABAA mechanism; short half-life (~2–4 h), metabolised to inactive products |
| Indications | Procedural/conscious sedation, pre-operative sedation, status epilepticus when no IV access (buccal/intranasal), ICU sedation |
| Adult dose | Procedural sedation: IV titrated 0.5–2 mg boluses; IM 5 mg; buccal for status: 10 mg |
| Paediatric dose | Buccal status: 5 mg (1–9 years), 10 mg (>10 years); premedication 0.25–0.5 mg/kg oral; procedural sedation 0.05–0.1 mg/kg IV titrated (with monitoring) |
| Adverse effects | Sedation, respiratory depression/apnoea (dose-related — monitor), amnesia, hypotension |
| Contraindications | As other benzodiazepines; must be given with monitoring and resuscitation available |
| Interactions | Additive respiratory depression with opioids (use reduced doses together); CYP3A4 inhibitors raise levels |
| Patient advice / monitoring | Hospital use with monitoring; airway equipment must be immediately available; complete amnesia is expected — reassure |
Buspirone (non-benzodiazepine anxiolytic)
Scroll the table sideways on a smaller screen.
| Buspirone — 5-HT1A partial agonist | |
|---|---|
| Mechanism | Partial agonist at presynaptic 5-HT1A autoreceptors → reduced serotonergic firing and gradual 5-HT adaptation; no GABA activity |
| Indications | Generalised anxiety disorder (chronic); SSRI augmentation; not useful acutely or in withdrawal syndromes |
| Adult dose | Start 5 mg 2–3 times daily; usual 15–30 mg/day; max 60 mg/day; effect over 2–4 weeks |
| Paediatric dose | Not established |
| Adverse effects | Dizziness, headache, nausea, nervousness; no sedation, amnesia, respiratory depression, dependence or withdrawal |
| Contraindications | MAOIs (risk of hypertension); severe hepatic/renal impairment (caution) |
| Interactions | MAOIs; CYP3A4 inhibitors (itraconazole, ritonavir) raise levels; inducers (rifampicin, carbamazepine) reduce effect |
| Patient advice / monitoring | Works slowly — take daily, not "as needed"; safe for long-term use and for patients with substance-use history; may reduce SSRI sexual side effects |
Propranolol (β-blocker for somatic anxiety)
Scroll the table sideways on a smaller screen.
| Propranolol — non-selective β-adrenergic antagonist | |
|---|---|
| Mechanism | Blocks β1/β2 receptors → blushes peripheral adrenergic symptoms (tremor, tachycardia, palpitations, sweating); crosses the blood–brain barrier |
| Indications | Performance/situational anxiety (exams, public speaking), tremor, adjunct in anxiety with somatic symptoms, hypertension, thyrotoxicosis symptoms, migraine prophylaxis |
| Adult dose | Performance anxiety: 10–40 mg 1 hour before the event; anxiety (off-label): 40–160 mg/day in divided doses |
| Paediatric dose | 0.2–0.5 mg/kg before events (specialist); otherwise not routine |
| Adverse effects | Fatigue, cold extremities, vivid dreams, bradycardia, hypotension; may mask hypoglycaemia and worsen asthma |
| Contraindications | Asthma/COPD with bronchospasm, severe bradycardia, 2nd/3rd-degree heart block, decompensated heart failure; caution in diabetes |
| Interactions | Additive bradycardia with verapamil/diltiazem, digoxin; masks tachycardia of thyrotoxicosis and hypoglycaemia |
| Patient advice / monitoring | Practice the dose before the big day (check tolerance); avoid abrupt withdrawal after chronic use (rebound tachycardia/hypertension); diabetics — watch for masked hypoglycaemia |
Pregabalin (α2δ ligand)
Scroll the table sideways on a smaller screen.
| Pregabalin — voltage-gated calcium-channel α2δ ligand | |
|---|---|
| Mechanism | Binds the α2δ subunit of presynaptic calcium channels → reduces excitatory neurotransmitter release; no GABA activity |
| Indications | Generalised anxiety disorder, neuropathic pain, fibromyalgia, adjunct in focal epilepsy |
| Adult dose | Start 75 mg twice daily; usual 150 mg twice daily; max 600 mg/day |
| Paediatric dose | Not recommended under 18 for anxiety |
| Adverse effects | Dizziness, somnolence, weight gain, oedema, blurred vision; euphoria/misuse potential at higher doses |
| Contraindications | Hypersensitivity; caution with substance-use history and renal impairment (dose-adjust) |
| Interactions | Additive sedation with opioids, alcohol, benzodiazepines; few CYP interactions |
| Patient advice / monitoring | Benefit builds over 1–2 weeks; dizziness on standing — rise slowly; report misuse urges; adjust dose in renal disease |
8 Choosing by Indication
Scroll the table sideways on a smaller screen.
| Presentation | Preferred approach |
|---|---|
| GAD, panic disorder, social anxiety (chronic) | SSRI/SNRI ± CBT; buspirone as alternative; benzodiazepines only short bridge at initiation if needed |
| Acute severe anxiety / panic attack | Benzodiazepine short course (e.g. diazepam/lorazepam days, not weeks) while SSRI starts |
| Situational/performance anxiety | Propranolol pre-event; skills training |
| Alcohol withdrawal | Chlordiazepoxide or diazepam fixed-dose or symptom-triggered regimen + thiamine |
| Status epilepticus / seizures | Lorazepam IV first-line; clobazam/clonazepam adjuncts |
| Insomnia | Sleep hygiene first; short Z-drug or short/intermediate benzodiazepine if needed, brief duration |
| Anxiety with depression | SSRI covers both; avoid long-term benzodiazepine monotherapy |
9 Dependence-Safe Prescribing Rules
- Have an exit plan before the first prescription — indication, expected duration (days to a few weeks), review date.
- Use the lowest effective dose, intermittent ("vocal naps") rather than around-the-clock where possible.
- Avoid in at-risk patients — history of substance use disorder, personality disorder, chronic insomnia as sole complaint.
- Never stop abruptly after regular use — taper; warn patients about rebound symptoms so they don't mistake them for relapse.
- Review at 2–4 weeks — continue only with clear indication; for chronic anxiety, transition to SSRI/CBT and taper the benzodiazepine.
- Document discussions, and prescribe small quantities.
10 Overdose & Management
- Isolated benzodiazepine overdose — usually benign: drowsiness, slurred speech, ataxia; deep coma is unusual unless co-ingestants. Manage supportively (airway, observation); activated charcoal, dialysis and whole-bowel irrigation have no role. Complications: aspiration pneumonia, rhabdomyolysis.
- Mixed overdose — danger multiplies with alcohol and opioids (respiratory depression); take a careful collateral history and treat the whole picture (naloxone for opioids).
- Flumazenil — see the section above: reserved for pure, known, single-agent iatrogenic/naive overdoses with airway support ready; contraindicated in chronic users, mixed ingestions (especially TCA), epilepsy and head injury.
11 Special Populations
- Elderly — high sensitivity: falls, cognitive impairment, paradoxical agitation; avoid long-acting agents (diazepam accumulates); if a benzodiazepine is unavoidable, use low-dose oxazepam/lorazepam (glucuronidated, no active metabolites); review sleep and anxiety for reversible causes first.
- Pregnancy & lactation — short-acting agents (lorazepam, oxazepam) preferred if essential; third-trimester exposure can cause neonatal sedation/withdrawal; avoid near delivery where possible.
- Substance-use disorders — avoid benzodiazepines except structured alcohol withdrawal; buspirone, SSRIs and CBT are the anxiolytic toolkit.
- Hepatic impairment — prefer glucuronidated agents (lorazepam, oxazepam, temazepam) over oxidised ones (diazepam, midazolam).
- Respiratory disease — caution in COPD/OSA and with opioids; benzodiazepines blunt the ventilatory response to CO₂.
12 Viva & Exam Points
- Mechanism — benzodiazepines ↑ GABAA chloride-channel opening frequency (safe in overdose alone); barbiturates prolong opening (lethal in overdose).
- Duration classes — short: midazolam; intermediate: lorazepam, alprazolam, oxazepam; long: diazepam, clonazepam.
- Chronic anxiety first-line — SSRI ± CBT; benzodiazepines are a short bridge only.
- Buspirone — 5-HT1A partial agonist; no dependence, no withdrawal, no acute effect; GAD only.
- Withdrawal — rebound anxiety, seizures, delirium; manage with slow taper (switch to diazepam).
- Flumazenil — competitive antagonist; seizures in chronic users and TCA co-ingestion; supportive care is the mainstay.
- Elderly — avoid long-acting agents; falls, amnesia, paradoxical reactions.
13 References
- Benzodiazepines. StatPearls. NCBI Bookshelf — class pharmacology and clinical use.
- Buspirone. StatPearls. NCBI Bookshelf — 5-HT1A mechanism, GAD indication, no dependence.
- Benzodiazepine Toxicity. StatPearls. NCBI Bookshelf — supportive management; flumazenil risks and withdrawal seizures.
- Flumazenil. StatPearls. NCBI Bookshelf — mechanism, contraindications, monitoring.
For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.